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Abstract
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with
myelodysplastic syndrome (MDS). However, the morbidity and mortality associated with
conventional HSCT have traditionally prevented many patients from undergoing such treatment.
Recent advances, including better prognostic algorithms, the introduction of reduced intensity
conditioning regimens, and experience with alternative donors, have made HSCT a realistic option
for an increasing number of patients with MDS.
Introduction and context
The myelodysplastic syndromes (MDSs) are a group of
clonal hematological stem cell disorders characterized by
defects in maturation resulting in cytopenias and a varied
risk of transformation to acute myeloid leukemia (AML).
Approximately 7,000–12,000 cases are diagnosed
annually in the United States [1]. The majority of
patients with MDS are older than 50 and the prognosis
is quite variable, with some patients never requiring any
intervention, and others needing treatment similar to
patients with acute leukemia [2,3]. For many years, the
French-American-British (FAB) classification distin-
guished five types of MDS [4]. The World Health
Organization (WHO) proposed revisions in 1999 that
included changing the definition of AML from 30%
blasts to 20%, recognizing that the percentage of blasts
is prognostic, stating that unilineage and multilineage
dysplasia are separate entities, and recognizing the 5q
-
syndrome [5]. The WHO system has again been recently
revised; there are now eight types of MDS (Table 1).
While classification systems aid in diagnosis and com-
munication, they are less helpful for predicting prognosis,
which is essential for a disease with multiple therapeutic
options. The International Prognostic Scoring System
(IPSS) was based on information from 816 patients with
MDS.Inthe IPSS, the numberofcytopenias,percentageof
blasts in the bone marrow, and cytogenetic abnormalities
were used to define four risk groups (low, intermediate-1,
intermediate-2, and high), which predicted overall
survival and risk of AML transformation (Table 2) [6].
The IPSS has subsequently become the most widely used
method to predict prognosis and assist in deciding which
patients should receive aggressive treatment.
Clinical manifestations of MDS are usually related to
cytopenias. The goals of treatment are to alleviate
symptoms, improve quality of life, and prolong survival.
Therapeutic options range from supportive care to
aggressive therapy. Patients who are elderly or with
significant comorbidities are usually supported with
transfusions, antibiotics, and growth factors. Recently,
three new therapies have been approved for treatment.
Lenalidomide, an analog of thalidomide, showed a
remarkable response in initial trials in patients with the
5q
- syndrome [7]. Studies in low-risk patients without
loss of 5q have also shown a significant response [8,9].
For higher risk patients, 5-azacitidine and decitabine,
which act through DNA demethylation, have been
approved for use. Both are given safely to outpatients,
but can induce significant cytopenias, especially during
the first few cycles [10–13]. Even with these new agents,
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the only curative therapy for MDS. However, HSCT
historically possesses significant morbidity and mortal-
ity, and given the heterogeneous prognosis of MDS, it
was not routinely offered to many patients.
Recent advances
Traditionally, only patients younger than 50 years of age
with an HLA-matched donor were eligible for HSCT,
however, improvements in prognostication, reduced
intensity conditioning regimens, and experience with
alternative donors have allowed physicians to consider
many formerly ineligible patients as potential candidates
for HSCT. Using registry data, investigators attempted to
define the best time to perform HSCT for patients with
MDS.Theirfindingsshowedthatforpatientswithlowand
intermediate-1 IPSS risk disease, a strategy of delayed
transplantation led to improved survival with the optimal
time for HSCT being the development of a new
cytogenetic abnormality, the appearance of a cytopenia,
or the progression to a higher risk IPSS group. For patients
with intermediate-2 and high IPSS disease, immediate
transplantation led to maximal overall survival [14].
Reduced intensity conditioning (RIC) regimens were
developed in the hope of decreasing acute transplant-
related mortality (TRM) while allowing patients with
advanced age or comorbidities to undergo HSCT. The
therapeutic mechanism of RIC-HSCT is an immunolo-
gical graft-versus-malignancy effect. Several different RIC
regimens have been published showing reasonable
toxicity in older patients [15–17]. There have also been
retrospective analyses comparing myeloablative and RIC
regimens in patients with MDS/AML with results
suggesting that while TRM is indeed lower with RIC,
relapse rates are higher, and overall and disease-free
survival appear equivalent [18–21]. To date, no pro-
spective randomized trials comparing conventional and
reduced intensity transplants have been performed,
however, it appears RIC-HSCT can offer approximately
a3 0 –40% chance of long-term remission with an
associated TRM between 15–40% for patients with MDS.
While the optimal HSCT donor remains a matched
relative, alternative donors, such as unrelated donors
(URDs) and umbilical cord blood (UCB), have become
reasonable options. With the emergence of DNA-based
Table 1. WHO classification for MDS [5]. Peripheral blood and bone marrow findings in myelodysplastic syndromes (MDS)
Disease Blood findings Bone marrow findings
Refractory cytopenias with unilineage dysplasia (RCUD):
Refractory anaemia (RA); Refractory neutropenia (RN);
Refractory thrombocytopenia (RT)
Unicytopenia or bicytopenia
1
No or rare blasts (<1%)
2
Unilineage dysplasia: ≥10% of the cells in one myeloid lineage
<5% blasts
<15% of erythroid precursors are ring sideroblasts
Refractory anaemia with ring sideroblasts (RARS) Anaemia
No blasts
≥15% of erythroid precursors are ring sideroblasts
Erythroid dysplasia only
<5% blasts
Refractory cytopenia with multilineage dysplasia (RCMD) Cytopenias(s)
No or rare blasts (<1%)
2
No Auer rods
<1×10
9/L monocytes
Dysplasia in ≥10% of the cells in two myeloid lineages
(neutrophil and/or erythroid precursors and/or megakar-
yocytes)
<5% blasts in marrow
No Auer rods
±15% ring sideroblasts
Refractory anaemia with excess blasts-1 (RAEB-1) Cytopenias(s)
<5% blasts
2
No Auer rods
<1×10
9/L monocytes
Unilineage or multilineage dysplasia
5–9% blasts
2
No Auer rods
Refractory anaemia with excess blasts-2 (RAEB-2) Cytopenias(s)
5–19% blasts
Auer rods ±
3
<1×10
9/L monocytes
Unilineage or multilineage dysplasia
10–19% blasts
Auer rods ±
3
Myelodysplastic syndrome – unclassified (MDS-U) Cytopenias
£1% blasts
2
Unequivocal dysplasia in less than 10% of cells in one or
more myeloid cell lines when accompanied by a cytogenetic
abnormality considered as presumptive evidence for a
diagnosis of MDS
<5% blasts
MDS associated with isolated del(5q) Anaemia
Usually normal or increased
platelet count
No or rare blasts (<1%)
Normal to increased megakaryocytes with hypobolated
nuclei
<5% blasts
Isolated del(5q) cytogenetic abnormality
No Auer rods
1 Bicytopenia may occasionally be observed. Cases with pancytopenia should be classified as MDS-U.
2 If the marrow myeloblast percentage is <5% but there are 2–4% myeloblasts in the blood, the diagnostic classification is RAEB 1. Cases of RCUD and
RMCD with 1% myeloblasts in the blood should be classified as MDS, U.
3 Cases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be classified as RAEB 2.
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significantly improved, mainly due to decreased TRM. A
few series of URD-HSCT in MDS have illustrated
encouraging results that approach the outcomes of those
with related donors [22–25]. In many centers, if a related
or unrelated donor is not available, UCB has emerged as
the preferred donor source. Several encouraging series of
UCB-HSCT have been reported, including our own series,
which shows a 14% 100-day TRM and a 67% 1-year
disease-free survival in various hematological malignan-
cies [26–29]. However, the experience with UCB-HSCT is
early, and we eagerly await longer follow-up.
Implications for clinical practice
Even with the introduction of several new therapies,
allogeneic HSCT remains the only curative treatment for
patients with MDS. Historically, the majority of patients
with MDS were not offered HSCT. Several recent
advances have allowed physicians to consider HSCT for
an increasing number of patients with MDS. Improved
prognostic algorithms and analyses have allowed better
prediction of disease outlook to permit aggressive
therapies to be tailored to high-risk patients. Recognition
of the graft-versus-malignancy effect in MDS and
introduction of reduced intensity regimens have enabled
many older patients to be considered for HSCT. In
addition, the growing experience with unrelated donors
and the use of umbilical cord blood has obviated the
requirement for a matched sibling. Even with this
progress, questions still remain. Future prognostic
systems will no doubt incorporate genetic and molecular
data in combination with the clinical information used
in the IPSS. Moreover, more experience with reduced
intensity regimens and alternative donors needs to be
gained before they become standard of care.
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